Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2a, Randomized, 2-Arm, Open-Label, Clinical Trial of the Efficacy of Linezolid Combined With Antituberculous Therapy in Subjects With Extensively Drug-Resistant (XDR) Pulmonary Tuberculosis
Brief Summary: This study, conducted in Masan and Seoul, South Korea, investigated the effectiveness of linezolid (LZD) in treating patients with extensively drug resistant tuberculosis (XDR TB). Because regular medicines do not work well against XDR TB, many more people die from it than from regular TB, which can be successfully treated by taking TB medication for 6 months. Linezolid has been used to treat other kinds of infections, but has not been well studied for TB. This study examined the side effects and effectiveness of prolonged treatment with linezolid at two different doses.

People 20 years of age and older who have XDR TB were eligible for this 3-year study.

Participants underwent the following tests and procedures:

* LZD treatment: Patients were randomly assigned to one of two study groups. Group 1 patients were observed for 2 months before starting LZD, while group 2 patients begin taking LZD right away. Both groups began with a 600 mg daily dose of LZD. After patients stopped coughing up TB germs (or after 4 months on LZD) they were randomly assigned either to continue taking 600 mg of LZD for the rest of the study or to take a decreased dose of 300 mg. In addition to LZD, patients continued to take their currently prescribed TB medications.
* Medical history.
* Physical examinations each month during treatment.
* Sputum collections once a week or more until 3 weeks after the patient was no longer contagious.
* Blood draws every week for 16 to 24 weeks and then once a month.
* Urine collections at several time points.
* Nerve and eye examinations before starting treatment and then monthly to look for possible LZD side effects.
* CT scans of the lungs three to four times the first year and once more later in the study. For this test the patient lay on a table within the doughnut-shaped CT scanner while special X-ray pictures are taken.

Patients who participated in a substudy had PET scans instead of the CT scans. For this test, the patient was given an injection into a vein of a radioactive chemical that can be detected by a special camera and viewed on a screen. The patient lay on a table within the doughnut-shaped scanner while pictures were taken.


Options:
A: Arm Label: HIV infected; Type: EXPERIMENTAL; Interventions: Drug: INH, Rifampicin, Ethambutol and Pyrazinamide | Arm Label: HIV negative; Type: ACTIVE_COMPARATOR; Interventions: Drug: INH, Rifampicin, Ethambutol and Pyrazinamide | Intervention Type: DRUG; Name: INH, Rifampicin, Ethambutol and Pyrazinamide; Assigned to Arm(s): HIV infected | Intervention Type: DRUG; Name: INH, Rifampicin, Ethambutol and Pyrazinamide; Assigned to Arm(s): HIV negative
B: Arm Label: Delayed Start Linezolid; Type: EXPERIMENTAL; Interventions: Drug: Delayed Start Linezolid | Arm Label: Immediate Start Linezolid; Type: EXPERIMENTAL; Interventions: Drug: Immediate Start Linezolid | Intervention Type: DRUG; Name: Immediate Start Linezolid; Assigned to Arm(s): Immediate Start Linezolid | Intervention Type: DRUG; Name: Delayed Start Linezolid; Assigned to Arm(s): Delayed Start Linezolid
C: Arm Label: Linezolid; Type: EXPERIMENTAL; Interventions: Drug: Linezolid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Linezolid; Assigned to Arm(s): Linezolid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Regimen 1; Type: EXPERIMENTAL; Interventions: Drug: Bedaquiline, Drug: Pretomanid, Drug: Moxifloxacin, Drug: Linezolid | Arm Label: Regimen 2; Type: EXPERIMENTAL; Interventions: Drug: Bedaquiline, Drug: Pretomanid, Drug: Linezolid, Drug: Clofazimine | Arm Label: Regimen 3; Type: EXPERIMENTAL; Interventions: Drug: Bedaquiline, Drug: Pretomanid, Drug: Linezolid | Arm Label: Control Regimen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB. | Intervention Type: DRUG; Name: Bedaquiline; Assigned to Arm(s): Regimen 1, Regimen 2, Regimen 3 | Intervention Type: DRUG; Name: Pretomanid; Assigned to Arm(s): Regimen 1, Regimen 2, Regimen 3 | Intervention Type: DRUG; Name: Moxifloxacin; Assigned to Arm(s): Regimen 1 | Intervention Type: DRUG; Name: Linezolid; Assigned to Arm(s): Regimen 1, Regimen 2, Regimen 3 | Intervention Type: DRUG; Name: Clofazimine; Assigned to Arm(s): Regimen 2 | Intervention Type: DRUG; Name: Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.; Assigned to Arm(s): Control Regimen

Answer: B